Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.33 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 4/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748795 | 0.79 | PARP1 (0.41) | PARP1GAKRIPK2COQ8ANLK | |
| SCHEMBL22758237 | 0.75 | KDM4E (0.48) | ALOX5APFEN1 | |
| SCHEMBL12880449 | 0.73 | APP (0.34) | PARP1GABRA1GABRB1GABRB2TYMS | |
| SCHEMBL12880400 | 0.69 | APP (0.33) | PARP1 | |
| SCHEMBL12880448 | 0.67 | DYRK1A (0.36) | PARP1TYMS | |
| SCHEMBL18503033 | 0.67 | PARP1 (0.39) | PARP1GABRA1GABRB1GABRB2CCNC | |
| SCHEMBL23857841 | 0.66 | GABRA1 (0.46) | GABRA1GABRB1GABRB2 | |
| SCHEMBL9967736 | 0.66 | GABRA1 (0.41) | GABRA1GABRB1GABRB2 | |
| SCHEMBL30169533 | 0.66 | GABRA1 (0.46) | GABRA1GABRB1GABRB2 | |
| SCHEMBL12182749 | 0.66 | PDPK1 (0.37) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252605-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTE RECH MED (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | CBR3, ADRB3, HRH4 | PARP1 3842/4885GAK 4108/4885RIPK2 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.